The largest database of trusted experimental protocols

3 protocols using sgc0946

1

Real-Time Cell Analysis of Epigenetic Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Real-time cell analysis (RTCA) was performed with xCELLigence (ACEA Bioscience, SD, USA) as described in [14 (link)]. 2 × 105 cells were used per well. The “normalized cell index” compares the change of impedance due to cellular coverage on a 16-well E-plate (Roche, Swiss) to a medium-only control. For inhibitor treatment, 5 μM SGC0946 (Sigma-Aldrich, MO, USA) or EPZ5676 (Absource Diagnostics, Germany), solved in dimethyl sulfoxide (DMSO, Sigma-Aldrich, MO, USA), was applied to CGNP 20 h after plating, for a duration of 4 h or 24 h. To CGN, the inhibitor was applied 4 h after plating, for the duration of 44 h. During RTCA, SGC0946 was replenished every 48 h with half a media change.
+ Open protocol
+ Expand
2

Epigenetic Modulators: Inhibitor Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The H3K4 methyltransferase LSD1 inhibitor S2101 was purchased from Merck Millipore (Burlington, MA, USA). The LSD1 inhibitor GSK2879552, H3K27 methyltransferase EZH2 inhibitor GSK126, and H3K79 methyltransferase DOT1L inhibitor EPZ-5676 were all purchased from Chemietek (Indianapolis, IN, USA). The H3K9 methyltransferase G9a inhibitor UNC0638, H3K27 demethylase JMJD3/UTX inhibitor GSKJ1, DOT1L inhibitor SGC0946, and MYC inhibitor 10058-F4 were all purchased from Sigma-Aldrich (St. Louis, MO, USA).
+ Open protocol
+ Expand
3

Murine Myeloid Cell Culture Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
MN cells from the spleens of tumor‐bearing mice were cultured in Anne Kelso modified Dulbecco's modified Eagle's medium (Low glucose DMEM (Invitrogen), 4 g/l glucose, 36 mg/l folic acid, 116 mg/l l‐arginine HCl, 216 mg/l l‐glutamine, 2 g/l NaHCO3, and 10 mM HEPES), supplemented with 20% fetal bovine serum (FBS) (Invitrogen), 0.1 mM l‐Asparagine (Sigma‐Aldrich), and 1% penicillin/streptomycin (Invitrogen). Cells were maintained at 37°C and 10% CO2. OCI‐AML3 and MOLM13 were purchased from the DSMZ. HEK293T, MV4‐11, and Kasumi‐1 cells were purchased from ATCC. OCI‐AML3, MOLM13, and MV4‐11 were cultured in RPMI‐1640 (Gibco) supplemented with 20% FBS, 1% pen/strep, and 100 µM Glutamax (Invitrogen) at 37°C and 5% CO2. HEK293T cells were cultured in DMEM (Gibco) supplemented with 10% FBS and 1% pen/strep. All cell lines in this study were routinely tested for Mycoplasma contamination. Cells were treated as indicated with AG636, PUGNAc (Sigma‐Aldrich), Cytarabine (Hospira), JQ1 (Bradner Lab), SGC0946 (Sigma‐Aldrich), Roscovitine (Assay Matrix), or DMSO (Sigma‐Aldrich). For the combination therapy, experiment drugs were refreshed every second day and cells were passaged every 2–4. To quantify the viable cells, cells were stained with 0.2 µg/ml DAPI for 15 min and analyzed by flow cytometry with CountBright™ Absolute Counting Beads (ThermoFisher).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!